HK Stock Market Move | NANJING PANDA(00553) rises nearly 7% as the 2025 Brain-Machine Interface Conference opens, marking a key stage in the domestic clinical translation.
Nanjing Panda Electronics Co., Ltd. (00553) rose nearly 7%, as of the time of reporting, rising by 6.81% to HK$4.86, with a turnover of HK$71.7075 million.
NANJING PANDA (00553) rose nearly 7%, as of press time, up 6.81% to 4.86 Hong Kong dollars, with a turnover of 71.7075 million Hong Kong dollars.
On the news front, on the afternoon of December 1, the Shanghai Science and Technology Commission held a press conference on the 2025 Brain-Machine Interface Conference. From December 4th to 5th, the 2025 Brain-Machine Interface Conference with the theme "Brain Connection World Wisdom Shanghai" will be held in the "Brain Intelligence Earth" Brain-Machine Interface Future Industry Cluster area. During the conference, through 1 main forum, 8 sub-forums, 1 product launch event, 1 developer forum, and 4 competitive events, the latest developments and application prospects of brain-machine interface technology will be fully presented.
It is reported that the cluster area is located in the Xian International Medical Investment Center in Minhang District, adjacent to the Hongqiao Campus of Fudan University Affiliated Huashan Hospital. Relying on the clinical resource advantages of the Department of Neurosurgery of Huashan Hospital, the Science and Technology Commission of Shanghai and the Minhang District government are building professional platforms for concept verification, testing and certification, and pilot processing in the cluster area, attracting and nurturing outstanding teams and enterprises from home and abroad to settle and develop, helping Shanghai to create a brain-machine interface innovation source and industrial highland with global influence.
The first domestic implantable brain-machine interface GCP clinical trial, the world's first real-time Chinese language decoding IIT trial, the first domestic brain-spine interface IIT trial, and the first domestic invasive brain-machine interface system prospective clinical trial have been successively carried out, and the related progress has also received high attention from international journals such as "Nature" and "MIT Technology Review".
Related Articles

HK Stock Market Move | ASCLETIS-B (01672) opened nearly 15% higher. Positive topline results were obtained from the 13-week Phase II study of ASC30 for the treatment of obesity.

Soochow International: Initiates "buy" rating for Ningbo Joyson Electronic Corp. (00699) with a target price of HK$23.

Thousand AISiasun Robot & Automation orders landed in Guangdong Jinma Entertainment Corporation (300756.SZ), performance expectations are high, institutions are optimistic.
HK Stock Market Move | ASCLETIS-B (01672) opened nearly 15% higher. Positive topline results were obtained from the 13-week Phase II study of ASC30 for the treatment of obesity.

Soochow International: Initiates "buy" rating for Ningbo Joyson Electronic Corp. (00699) with a target price of HK$23.

Thousand AISiasun Robot & Automation orders landed in Guangdong Jinma Entertainment Corporation (300756.SZ), performance expectations are high, institutions are optimistic.

RECOMMEND

Baidu’s AI Ace Kunlunxin Prepares For Hong Kong IPO, Domestic Computing Power Faces Crucial Test
08/12/2025

Institutions Say Short-Term Volatility Does Not Alter Upward Trend Of Hong Kong Stocks, Hang Seng Index Still Expected To Challenge 30,000 Points Next Year
08/12/2025

As The 2025 Central Economic Work Conference Approaches, What New Expectations Lie Ahead For Next Year’s Economic Agenda? Institutions Forecast Five Key Highlights
08/12/2025


